DEA Hosts Public Listening Sessions on Telemedicine Regulations
MEDIA ADVISORY - UPDATED
WASHINGTON – The Drug Enforcement Administration will host public listening sessions to receive comments from healthcare practitioners, experts, advocates, patients, and other members of the public to inform DEA’s regulations on prescribing controlled substances via telemedicine.
The listening sessions will be held in person and livestreamed with remote participation available.
WHAT: Public Listening Sessions on Telemedicine Regulations
WHO: Open to the public
WHEN: September 12-13, 2023
WHERE: DEA Headquarters
700 Army Navy Drive
Arlington, Va. 22202
Note: Registration for members of the public to attend in person or make oral presentations has now closed. The event will be livestreamed and publicly available.
FOR NEWS MEDIA: News media wishing to attend in person must RSVP to DEA.Public.Affairs@dea.gov by 5 p.m. on September 11, 2023. Members of the media should arrive no later than 8 a.m. on September 12 and 13 for setup.
For more information, visit Federal Register: Practice of Telemedicine: Listening Sessions.
For additional questions, email DPW@DEA.gov
On March 1, 2023, DEA, in concert with the Department of Health and Human Services (HHS), issued notices of proposed rulemakings (NPRM) to allow for prescribing of certain controlled medications via telemedicine without an in-person medical evaluation of the patient under circumstances that are consistent with public health, safety, and effective controls against diversion. On May 9, DEA and HHS announced the extension of COVID-19 telemedicine flexibilities for an additional six months while considering the more than 38,000 comments from the public on the NPRMs.
# # #